Ceragenix Pharmaceuticals, Inc. and Dr. Reddy’s Laboratories, Inc. Enter Into Distribution and Supply Agreement for EpiCeram(R)

DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCB:CGXP), a biopharmaceutical company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the “Agreement”) with Dr. Reddy’s Laboratories, Inc., a subsidiary of Dr. Reddy’s Laboratories Limited (NYSE:RDY), to commercialize EpiCeram®, a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in the United States.